International Journal of Pharmaceutical Medicine

, Volume 20, Issue 6, pp 367–372

Human Subjects Protections in Clinical Drug Trials in China

A Focus on the Institute Level
  • Jiaqi Xu
  • Benfu Li
  • Qiang Ma
  • Haitao Heidi Liu
  • Yali Cong
Special Section on Medicines Development in China Focus on China

Abstract

With the increasing number of clinical trials being undertaken in China over the last few years, stakeholders in human subjects protections (HSP) are facing many new challenges; currently, these challenges in HSP are largely taken up by the ethical review committees and study investigators. This article identifies a number of issues with the present system and suggests ways to resolve these issues at the institutional level. Though the Chinese government has developed a basic regulatory framework for HSP, further work still needs to be done.

It is imperative that China develops a robust and reliable HSP system at the institutional level as drug studies are increasingly being undertaken in mainland China.

References

  1. 1.
    Operational guidelines on clinical study sites. No. 14 file of “Wei Yao”. Beijing: Ministry of Health, 1995Google Scholar
  2. 2.
    Good clinical practice in drug clinical trials. Beijing: Ministry of Health, 1998Google Scholar
  3. 3.
    Good clinical practice in drug clinical trials. Beijing: Ministry of Health, 2003Google Scholar
  4. 4.
    Tian S. Drug clinical trials and GCP. Beijing: Peking University Medical Press, 2003: 97Google Scholar
  5. 5.
    CCMO [online]. Available from URL: http://www.ccmo-online.nl/main.asp?.pid=14&sid=15 [Accessed 2006 Jun 30]
  6. 6.
    Emanuel EJ, Wood AW, Fleischman A, et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med 2004 Aug 17; 141 (4): 282–91PubMedGoogle Scholar
  7. 7.
    Gunsalus CK, Bruner EM, Burbules NC, et al. Mission creep in the IRB world. Science 2006 Jun 9: 312 (5779): 1441 [online]. Available from URL: http://www.sciencemag.org/cgi/content/summary/312/5779/1441 [Accessed 2006 Sep 25]PubMedCrossRefGoogle Scholar
  8. 8.
    Federman DD, Hanna KE, Lyman L, et al., editors, for the Committee on Assessing the System for Protecting Human Research Participants. Responsible research: a systems approach to protecting research participants [online]. Available from URL: http://www.iom.edu/CMS/3740/4870/4459.aspx [Accessed 2006 Oct 4]Google Scholar
  9. 9.
    European Parliament. Directive 2001/20/EC: the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use [online]. Available from URL: http://eudract.emea.eu.int/docs/Dir2001-20_en.pdf [Accessed 2006 Sep 17]
  10. 10.
    Main results of the third investigation of national healthcare [online]. Available from URL: http://www.moh.gov.cn/uploadfile/200412/200412314857549.doc [Accessed 2006 Jun 20]

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Jiaqi Xu
    • 1
  • Benfu Li
    • 2
  • Qiang Ma
    • 2
    • 3
  • Haitao Heidi Liu
    • 4
  • Yali Cong
    • 5
  1. 1.Department of Drug Safety and InspectionState Food and Drug AdministrationBeijingChina
  2. 2.Chinese Medical Ethics AssociationBeijingChina
  3. 3.Shanghai Health BureauShanghaiChina
  4. 4.Forum for Ethical Review Committees in Asia and the Western Pacific (FERCAP)BangkokThailand
  5. 5.Medical Ethics ProgramPeking University Health Science CenterBeijingPeople’s Republic of China

Personalised recommendations